| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.76 [0.69, 0.84] | | < 1 | | 37% | 10 studies (10/-) | 100.0 % | low | low | high | crucial | - |
| deaths (OS) (extension) | 0.68 [0.60, 0.78] | | < 1 | | 0% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| PFS (extension) | 0.61 [0.53, 0.70] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| progression or deaths (PFS) | 0.63 [0.55, 0.73] | | < 1 | | 56% | 7 studies (7/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| DCR | 1.17 [0.92, 1.50] | | > 1 | | 0% | 2 studies (2/-) | 90.1 % | low | not evaluable | high | non important | - |
| DOR | 0.59 [0.38, 0.92] | | < 1 | | 45% | 2 studies (2/-) | 99.0 % | low | not evaluable | high | non important | - |
| objective responses (ORR) | 2.45 [1.41, 4.26] | | > 1 | | 86% | 10 studies (10/-) | 99.9 % | low | low | high | non important | - |
safety endpoints 00 |
| AE (any grade) | 2.19 [1.17, 4.10] | | < 1 | | 0% | 5 studies (5/-) | 0.7 % | low | not evaluable | high | non important | - |
| AE (grade 3-4) | 1.47 [0.83, 2.62] | | < 1 | | 88% | 5 studies (5/-) | 9.5 % | low | not evaluable | high | non important | - |
| AE leading to death (grade 5) | 2.39 [0.21, 27.48] | | < 1 | | 0% | 2 studies (2/-) | 24.4 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (any grade) | 2.58 [1.16, 5.75] | | < 1 | | 0% | 1 study (1/-) | 1.0 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 0.65 [0.46, 0.92] | | < 1 | | 0% | 2 studies (2/-) | 99.3 % | some concern | not evaluable | moderate | non important | - |
| STRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 1.55 [1.00, 2.42] | | < 1 | | 88% | 10 studies (10/-) | 2.5 % | low | low | high | non important | - |
| TRAE (grade 3-4) | 1.46 [0.82, 2.60] | | < 1 | | 92% | 10 studies (10/-) | 10.2 % | low | low | high | non important | - |
| TRAE leading to death (grade 5) | 1.58 [0.62, 4.04] | | < 1 | | 0% | 7 studies (7/-) | 16.8 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 1.41 [0.96, 2.08] | | < 1 | | 54% | 6 studies (6/-) | 4.2 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 2.20 [1.54, 3.14] | | < 1 | | 0% | 5 studies (5/-) | 0.0 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.43 [0.27, 7.58] | | < 1 | | 0% | 4 studies (4/-) | 33.8 % | low | not evaluable | high | non important | - |
| Alopecia TRAE (grade 3-4) | 0.94 [0.13, 6.69] | | < 1 | | 0% | 4 studies (4/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.25 [0.05, 1.30] | | < 1 | | 36% | 4 studies (4/-) | 95.0 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.95 [0.19, 4.70] | | < 1 | | 0% | 4 studies (4/-) | 52.7 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.57 [0.15, 2.25] | | < 1 | | 0% | 4 studies (4/-) | 78.8 % | some concern | not evaluable | moderate | non important | - |
| Chills TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 1.17 [0.46, 2.99] | | < 1 | | 71% | 9 studies (9/-) | 36.9 % | low | not evaluable | high | non important | - |
| Constipation TRAE (grade 3-4) | 0.94 [0.13, 6.69] | | < 1 | | 0% | 4 studies (4/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
| Cough TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.94 [0.13, 6.69] | | < 1 | | 0% | 4 studies (4/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 1.85 [0.06, 55.43] | | < 1 | | 0% | 1 study (1/-) | 36.3 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.46 [0.73, 2.94] | | < 1 | | 45% | 9 studies (9/-) | 14.2 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 0.94 [0.13, 6.69] | | < 1 | | 0% | 4 studies (4/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
| Dyspnoea TRAE (grade 3-4) | 0.70 [0.08, 6.00] | | < 1 | | 0% | 2 studies (2/-) | 62.7 % | some concern | not evaluable | moderate | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 1.55 [0.34, 6.97] | | < 1 | | 68% | 4 studies (4/-) | 28.5 % | low | not evaluable | high | non important | - |
| Eye disorders TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.35 [0.15, 0.82] | | < 1 | | 0% | 4 studies (4/-) | 99.2 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 2.16 [0.84, 5.60] | | < 1 | | 69% | 4 studies (4/-) | 5.6 % | low | not evaluable | high | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Headache TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Hepatitis TRAE (grade 3-4) | 2.42 [1.01, 5.83] | | < 1 | | 0% | 9 studies (9/-) | 2.4 % | low | not evaluable | high | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 0.53 [0.15, 1.80] | | < 1 | | 0% | 3 studies (3/-) | 84.6 % | low | not evaluable | high | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 6.01 [0.30, 120.38] | | < 1 | | 0% | 1 study (1/-) | 12.3 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.69 [0.13, 3.57] | | < 1 | | 0% | 5 studies (5/-) | 67.3 % | some concern | serious | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.02 [0.50, 2.10] | | < 1 | | 0% | 8 studies (8/-) | 47.4 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.06 [0.31, 3.60] | | < 1 | | 0% | 9 studies (9/-) | 46.2 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 1.47 [0.24, 8.98] | | < 1 | | 70% | 7 studies (7/-) | 33.8 % | low | not evaluable | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.34 [0.53, 10.34] | | < 1 | | 63% | 7 studies (7/-) | 13.2 % | low | serious | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.07 [0.01, 0.50] | | < 1 | | 0% | 2 studies (2/-) | 99.5 % | some concern | not evaluable | moderate | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.22 [0.29, 5.20] | | < 1 | | 0% | 5 studies (5/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
| Myalgia TRAE (grade 3-4) | 0.94 [0.22, 4.02] | | < 1 | | 0% | 4 studies (4/-) | 53.2 % | some concern | not evaluable | moderate | non important | - |
| Myositis TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 0.29 [0.07, 1.29] | | < 1 | | 0% | 4 studies (4/-) | 94.7 % | some concern | not evaluable | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 0.46 [0.04, 5.09] | | < 1 | | 0% | 2 studies (2/-) | 73.5 % | some concern | not evaluable | moderate | non important | - |
| Nervous system disorders TRAE (grade 3-4) | 8.03 [0.42, 152.51] | | < 1 | | 0% | 1 study (1/-) | 8.5 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.18 [0.04, 0.96] | | < 1 | | 0% | 4 studies (4/-) | 97.7 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 1.61 [0.21, 12.50] | | < 1 | | 0% | 3 studies (3/-) | 32.5 % | some concern | not evaluable | moderate | non important | - |
| Pancytopenia TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.63 [0.10, 3.88] | | < 1 | | 0% | 4 studies (4/-) | 69.0 % | some concern | not evaluable | moderate | non important | - |
| Pericarditis TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.61 [0.10, 3.86] | | < 1 | | 6% | 3 studies (3/-) | 70.0 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.19 [0.55, 8.66] | | < 1 | | 0% | 5 studies (5/-) | 13.2 % | some concern | not evaluable | moderate | non important | - |
| Polymyalgia Rheumatica TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.72 [0.08, 6.18] | | < 1 | | 0% | 3 studies (3/-) | 61.7 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 1.25 [0.43, 3.64] | | < 1 | | 0% | 9 studies (9/-) | 34.2 % | low | not evaluable | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 2.09 [0.82, 5.28] | | < 1 | | 0% | 9 studies (9/-) | 6.1 % | low | not evaluable | high | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 8.03 [0.42, 152.51] | | < 1 | | 0% | 1 study (1/-) | 8.5 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 1.79 [0.77, 4.18] | | < 1 | | 0% | 4 studies (4/-) | 8.9 % | low | not evaluable | high | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.18 [0.03, 1.07] | | < 1 | | 0% | 2 studies (2/-) | 97.0 % | some concern | not evaluable | moderate | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.49 [0.11, 19.48] | | < 1 | | 0% | 2 studies (2/-) | 38.1 % | low | not evaluable | high | non important | - |
| Uveitis TRAE (grade 3-4) | 0.95 [0.18, 4.96] | | < 1 | | 0% | 5 studies (5/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.64 [0.11, 3.72] | | < 1 | | 0% | 5 studies (5/-) | 68.8 % | low | not evaluable | high | non important | - |
| Vomiting TRAE (grade 3-4) | 0.38 [0.10, 1.43] | | < 1 | | 0% | 4 studies (4/-) | 92.4 % | some concern | not evaluable | moderate | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.46 [0.04, 5.09] | | < 1 | | 0% | 2 studies (2/-) | 73.5 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 0.40 [0.20, 0.79] | | < 1 | | 0% | 4 studies (4/-) | 99.6 % | low | not evaluable | high | non important | - |
| Anaemia AE (grade 3-4) | 0.44 [0.23, 0.84] | | < 1 | | 12% | 3 studies (3/-) | 99.3 % | low | not evaluable | high | non important | - |
| Asthenia AE (grade 3-4) | 0.17 [0.02, 1.39] | | < 1 | | 0% | 1 study (1/-) | 95.0 % | NA | not evaluable | | non important | - |
| Chills AE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.80 [0.27, 2.38] | | < 1 | | 0% | 4 studies (4/-) | 65.8 % | low | not evaluable | high | non important | - |
| Cough AE (grade 3-4) | 0.99 [0.17, 5.76] | | < 1 | | 0% | 4 studies (4/-) | 50.2 % | low | not evaluable | high | non important | - |
| Decreased appetite AE (grade 3-4) | 0.65 [0.31, 1.39] | | < 1 | | 0% | 4 studies (4/-) | 86.6 % | low | not evaluable | high | non important | - |
| Diarrhoea AE (grade 3-4) | 3.93 [0.81, 19.19] | | < 1 | | 66% | 4 studies (4/-) | 4.6 % | low | not evaluable | high | non important | - |
| Dyspnoea AE (grade 3-4) | 1.03 [0.50, 2.13] | | < 1 | | 25% | 4 studies (4/-) | 46.5 % | low | not evaluable | high | non important | - |
| Fatigue AE (grade 3-4) | 1.58 [0.84, 2.97] | | < 1 | | 46% | 4 studies (4/-) | 7.6 % | low | not evaluable | high | non important | - |
| Headache AE (grade 3-4) | 0.78 [0.33, 1.84] | | < 1 | | 8% | 4 studies (4/-) | 71.8 % | low | not evaluable | high | non important | - |
| Increase AST AE (grade 3-4) | 18.42 [5.64, 60.14] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 34.83 [8.39, 144.67] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.88 [0.42, 1.83] | | < 1 | | 0% | 4 studies (4/-) | 63.8 % | low | not evaluable | high | non important | - |
| Pruritus AE (grade 3-4) | 10.35 [0.56, 190.49] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 0.48 [0.12, 1.91] | | < 1 | | 0% | 4 studies (4/-) | 84.9 % | low | not evaluable | high | non important | - |
| Rash AE (grade 3-4) | 6.16 [0.31, 123.62] | | < 1 | | 0% | 1 study (1/-) | 12.0 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 1.13 [0.57, 2.24] | | < 1 | | 0% | 4 studies (4/-) | 36.2 % | low | not evaluable | high | non important | - |
| Weight decreased AE (grade 3-4) | 1.02 [0.06, 16.34] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
